RxDoctor Payments Data

Susan McGee, NP

Family · Missoula, MTNPI 1528238078

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,269 of the $1,655 with a category attached, or 76.7%. 8 manufacturers reported payments, led by AbbVie at 56.5% of the total.

$1,655in general payments, 2019–2025

Across 113 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$934
  • Teva Pharmaceuticals USA, Inc.$260
  • Pfizer$153
  • Biogen$150
  • Livanova USA, Inc.$74
  • Neurocrine Biosciences, Inc.$56
  • plus $28 from 2 others

What the payments were for

  • Consulting fees$1509%
  • Food & beverage$1,26977%
  • Education$23514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,655 in reported general payments places this provider in the 85th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$16,591
Medicare patients
50
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)16$250,469
UbrelvyUbrogepant27$38,746
Emgality PenGalcanezumab-Gnlm41$28,442
Lacosamide48$27,269
Topiramate ErTopiramate12$11,476
Levetiracetam80$2,839
Lamotrigine151$2,359
Zonisamide46$1,737
Carbidopa-Levodopa ErCarbidopa/Levodopa29$1,512
Sumatriptan Succinate21$1,416
Oxcarbazepine11$1,278
Donepezil Hcl20$725
Pregabalin25$594
Tizanidine Hcl51$559
Topiramate31$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$934$38,74627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 family providers in Montana.

Other family in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →